Pharmamar

This early-phase study tested a new drug called PM14 in 126 people with advanced solid tumors that had not responded to standard treatments. The main goals were to find the safest dose and to see if the drug could shrink tumors or slow their growth. The study is now complete, and…

This phase 3 study tested two experimental treatments (lurbinectedin alone or with irinotecan) against standard options (topotecan or irinotecan) in 705 adults with small cell lung cancer that returned after initial platinum-based chemo. The goal was to see if the new approaches …

This study looked at how itraconazole, a strong CYP3A4 inhibitor, changes the way the body processes lurbinectedin in people with advanced solid tumors. It involved 14 participants and used a two-way crossover design to measure drug levels in the blood. The goal was to understand…

This study looked at how bosentan, a drug that affects liver enzymes, changes the way the body processes the cancer drug lurbinectedin. It involved 11 adults with advanced solid tumors who had no other treatment options. The goal was to measure drug levels in the blood to underst…